The semaglutide impurity des-16-Gly-SMT is a structural defect impurity generated during the synthesis or storage of semaglutide (a long-acting GLP-1 receptor agonist hypoglycemic drug). The impurity molecule lacks the 16th glycine (Gly) residue, while retaining the SMT modified fragment. As a key process-related impurity, its presence may affect the biological activity and stability of the drug. The content of this impurity needs to be strictly monitored in drug quality control to ensure that the safety and efficacy of the drug meet the pharmacopoeia standards.
Product Overview
Basic Description |
Structure and function: |
Three-letter sequence |
H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gln-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Asp-Val-Arg-Arg-Arg-Arg-Arg-Arg-Gly-CONH2 |
Single letter sequence |
HHAEGTFTSDVSSYLEQAKKEFIAWLVKGDVRRAARRRRG-NH2 |
Molecular formula |
C183H284N51O56S |
Molecular weight |
4034.16 g/mol |
Product Attributes
purity |
>98% |
form |
Lyophilized powder |
Storage conditions |
Store at -20°C/-80°C away from light |